Babio Launches Vibrio Cholerae Rapid Antigen Detection Kit
BABIO Biotechnology (BABIO), a leading Chinese manufacturer of in vitro diagnostic products, has introduced its Vibrio Cholerae Antigen Detection Kit (Colloidal Gold Method) to global markets including Europe, America, Africa, and Southeast Asia.
This rapid lateral flow immunoassay detects Vibrio cholerae O1 and O139 antigens in fecal specimens within 15 minutes, offering a valuable screening tool for outbreaks and emergency response. Designed for ease of use by minimally trained personnel, the kit provides fast, reliable results without the need for laboratory equipment.
Key Highlights
-
Target Pathogens: Vibrio cholerae O1, O139
-
Result Time: 15 minutes
-
Format: Test card or strip
-
Certifications: Manufactured under strict GMP & ISO standards
Cholera remains a global health challenge with frequent outbreaks in Africa and Asia. Rapid, accurate detection is essential for early intervention, effective treatment, and outbreak control. BABIO’s solution delivers cost-effective, field-ready diagnostics trusted by healthcare providers worldwide.
Learn more about Babio’s full diagnostic portfolio at: https://www.babiocorp.com
#CholeraTest #VibrioCholerae #RapidTestKit #OutbreakResponse #BabioBiotech #GlobalHealth #InVitroDiagnostics